Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was suspended by QTultrasound as other studies were reprioritized.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Analysis Group, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
This study aims to characterize patient experience, satisfaction and preference for use of the QT Scanner in comparison to mammography by directly engaging women who have experience with both technologies.
The objectives will be addressed by first conducting structured one-on-one interviews with about 20 women (Qualitative Phase), and then administering a web-based patient survey with quantitative measurements in about 200 women (Quantitative Phase). The current Protocol registration pertains to the first, qualitative phase of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| QT Scanner in comparison to mammography | Women who have experience with both technologies (QT Scanner/Breast mammography |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| QT Scanner | Diagnostic Test | Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast. |
| Measure | Description | Time Frame |
|---|---|---|
| Qualitative phase: structured one-on-one interviews | one-on-one interviews will be conducted by trained professionals with about 20 women | 30 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
• Excluded if all Inclusion Criteria are not met
Not provided
Not provided
Not provided
The study target population are women who have experience with both the QT Scanner and mammography.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Analysis Group, Inc. | Boston | Massachusetts | 02199 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 14627058 | Background | Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M; PRO Harmonization Group. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003 Sep-Oct;6(5):522-31. doi: 10.1046/j.1524-4733.2003.65309.x. | |
| 27066193 |
| Label | URL |
|---|---|
| National Cancer Institute S, Epidemiology, and End Results Program,. Cancer Stat Facts: Female Breast Cancer. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Background |
| Blumen H, Fitch K, Polkus V. Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service. Am Health Drug Benefits. 2016 Feb;9(1):23-32. |
| 27712700 | Background | Johnson FR, Zhou M. Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective. Value Health. 2016 Sep-Oct;19(6):741-745. doi: 10.1016/j.jval.2016.04.008. |
| National Breast Cancer Foundation I. Facts about breast cancer in the United States. 2019 | View source |
| American Cancer Society. Breast Cancer Facts \& Figures 2017-2018. | View source |